Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Drugs

12-03-2025 | Acute Myeloid Leukemia | AdisInsight Report

Revumenib: First Approval

Author: Yahiya Y. Syed

Published in: Drugs

Login to get access

Abstract

Revumenib (Revuforj®) is an oral, first-in-class menin inhibitor developed by Syndax Pharmaceuticals for the treatment of KMT2A-rearranged (KMT2Ar) acute leukaemia, NPM1-mutated (NPM1m) acute myeloid leukaemia (AML) and solid tumours. The interaction between menin and the KMT2A protein complex leads to aberrant gene expression, driving leukaemogenic transcription. By blocking this interaction, revumenib promotes differentiation and exerts antileukaemic activity in KMT2Ar acute leukaemias and other menin inhibition-sensitive leukaemias. Revumenib received its first approval on 15 November 2024 in the USA for the treatment of relapsed or refractory (R/R) acute leukaemia with a KMT2A translocation in adult and paediatric patients 1 year and older. This article summarizes the milestones in the development of revumenib leading to this first approval.
Appendix
Available only for authorised users
Literature
1.
Issa GC, Ravandi F, DiNardo CD, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482–95.CrossRefPubMed
2.
Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(9):162.CrossRefPubMedPubMedCentral
3.
4.
Syndax Pharmaceuticals. Syndax announces FDA approval of Revuforj® (revumenib), the first and only menin inhibitor to treat adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation [media release]. 15 Nov 2024. https://​ir.​syndax.​com/​.
5.
6.
7.
Adriaanse FRS, Schneider P, Arentsen-Peters STCJM, et al. Distinct responses to menin inhibition and synergy with DOT1L inhibition in KMT2A-rearranged acute lymphoblastic and myeloid leukemia. Int J Mol Sci. 2024;25(6020):1–14.
8.
Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024;43(1):75–84.CrossRefPubMed
9.
Fleischmann M, Bechwar J, Voigtländer D, et al. Synergistic effects of the RARalpha agonist tamibarotene and the menin inhibitor revumenib in acute myeloid leukemia cells with KMT2A rearrangement or NPM1 Mutation. Cancers (Basel). 2024;16(1311):1–16.
10.
11.
Zeidner JF, Lin TL, Welkie R, et al. Phase 1b study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: interim results of dose escalation from the Beat AML Consortium [abstact S134 plus presentation]. In: 29th Congress of the European Haematology Association. 2024.
12.
Shukla N, Guest E, Tasian SK, et al. Safety and activity of revumenib in combination with fludarabine/cytarabine (FLA) in patients with relapsed/refractory acute leukemias [abstract no. P450 plus presentation]. In: 29th Congress of the European Haematology Association. 2024.
13.
Issa GC, Cuglievan B, Daver N, et al. Phase I/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in R/R AML [abstract no. 216]. In: 66th American Society of Hematology Annual Meeting. 2024.
14.
Loo S, Iland HJ, Tiong IS, et al. Revumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged acute myeloid leukemia: a domain of the multi-arm ALLG AMLM26 INTERCEPT platform trial [abstract no. 223]. In: 66th American Society of Hematology Annual Meeting. 2024.
15.
Aldoss I, Issa GC, Thirman MJ, et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: efficacy and safety results from the AUGMENT-101 phase 1/2 study [abstract plus poster 2907]. Blood. 2023;142(Suppl 1):2907–9.CrossRef
16.
Zwaan CM, Shukla N, Karras N, et al. Pivotal phase 2 results of AUGMENT-101 for revumenib in KMT2Ar acute leukemia: pediatric experience [abstract plus poster 2002]. Pediatr Blood Cancer. 2024;71(Suppl 3):S2–3.
17.
18.
Zucenka A, Issa GC, Arellano M, et al. Revumenib maintenance therapy following revumenib-induced remission and transplant [abstract plus poster 4950]. Blood. 2023;142(Suppl 1):4950–2.CrossRef
19.
Rubnitz J, Issa GC, Stein EM, et al. Revumenib in patients with acute leukemias: compassionate use program experience [abstract no. P561 plus poster]. HemaSphere. 2023;7(Suppl 3):981–2.
20.
Parikh A, Radojcic V, Clancy M, et al. Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors [abstract no. TPS227]. J Clin Oncol. 2024;42(Suppl 3):TPS227.CrossRef
Metadata
Title
Revumenib: First Approval
Author
Yahiya Y. Syed
Publication date
12-03-2025
Publisher
Springer International Publishing
Published in
Drugs
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-025-02161-5